AZ looks to grow reach in lupus with phase 3 win for self-administered Saphnelo
January 6, 2026
The full results from AstraZeneca’s phase 3 Tulip-SC trial build on the interim results that earned the drug a European
The full results from AstraZeneca’s phase 3 Tulip-SC trial build on the interim results that earned the drug a European
Oral semaglutide, which Novo has taken to calling “Wegovy in a pill,” is expected to receive an FDA decision before
High-burden patient segments are driving opportunity for novel pipeline agents, while JAK inhibitors led by AbbVie’s Rinvoq continue to generate strong future
Strong physician readiness, high efficacy expectations, and anticipated displacement of off-label rituximab position Gazyvaro for rapid adoption across Europe EXTON,
US primary care physicians and endocrinologists indicate strong intent to prescribe oral semaglutide for weight loss, despite relatively low pre-approval
Spherix Global Insights’ Latest Market Dynamix™ Report Reveals Intensifying Complexity in Relapsed/Refractory Multiple Myeloma Ahead of ASH 2025 Exton, PA.,
One-month post-launch, Gazyva’s perceived degree of advance exceeds benchmarks achieved by GSK’s Benlysta and Aurinia’s Lupkynis at comparable post-launch time
New chart-audit data reveal faster referrals, more patients initiating advanced therapy before hematology consultation, and heightened disease awareness among community physicians. Exton,
New insights from Spherix Global Insights reveal strong rheumatologist anticipation for next-generation oral and multi-pathway innovations, including Sotyktu, icotrokinra, and
Physicians highlight early intervention, safety, and access limitations as key unmet needs—Tepezza SC anticipated to reshape the treatment paradigm in
Familiarity with AstraZeneca’s Saphnelo and enthusiasm for next-generation biologics signal increasing optimism, though CAR T-cell therapy divides opinion amid safety
Strong enthusiasm for novel modalities is tempered by neurologists’ demands for clinically meaningful endpoints and data superiority, according to Spherix
